Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2016-09-20
- Target Recruit Count
- 600
- Registration Number
- NCT00121303
- Locations
- 🇬🇧
University Hospital of Wales, Cardiff, Wales, United Kingdom
🇬🇧Medway Maritime Hospital, Gillingham Kent, England, United Kingdom
🇬🇧North Hampshire Hospital, Basingstoke, England, United Kingdom
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Vion Pharmaceuticals
- Target Recruit Count
- 420
- Registration Number
- NCT00112554
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States
S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Biological: filgrastimDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicinDrug: dexamethasoneDrug: doxorubicinDrug: leucovorinDrug: mercaptopurineDrug: methotrexateDrug: mitoxantroneDrug: AsparaginaseDrug: prednisoneDrug: thioguanineDrug: vincristineRadiation: radiation therapyDrug: allopurinolDrug: bactrim
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 79
- Registration Number
- NCT00109837
- Locations
- 🇺🇸
Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
🇺🇸Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸Minor and James Medical, PLLC, Seattle, Washington, United States
Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2010-09-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00107523
- Locations
- 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant
- Conditions
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2010-09-20
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00107354
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-02-08
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 5377
- Registration Number
- NCT00103285
- Locations
- 🇺🇸
Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States
🇺🇸Driscoll Children's Hospital, Corpus Christi, Texas, United States
🇨🇦Centre Hospitalier Universitaire de Sherbrooke-Fleurimont, Sherbrooke, Quebec, Canada
Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 24
- Registration Number
- NCT00101153
- Locations
- 🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 47
- Registration Number
- NCT00098774
- Locations
- 🇺🇸
Saint Luke's Hospital - South, Overland Park, Kansas, United States
🇺🇸Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees, New Jersey, United States
🇺🇸SUNY Upstate Medical University Hospital, Syracuse, New York, United States
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Interventions
- Drug: L-asparaginaseDrug: doxorubicin hydrochlorideDrug: therapeutic hydrocortisoneDrug: vincristine sulfateBiological: epratuzumabDrug: cytarabineDrug: prednisoneDrug: pegaspargaseDrug: dexrazoxane hydrochlorideDrug: methotrexateDrug: etoposideDrug: cyclophosphamideDrug: leucovorin calciumBiological: filgrastim
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 134
- Registration Number
- NCT00098839
- Locations
- 🇺🇸
Indiana University Medical Center, Indianapolis, Indiana, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Interventions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00098423
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.